[Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech C]
[Sinovac Secures $15 Million in Funding to Accelerate COVID-19 Vaccine Development BEIJING, May 22, 2020 -- (BUSINESS WIRE) -- Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced a transaction in which Advantech C]
[Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital SEC Order found Li and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sinovac The SEC also found that the participants in the activist plan were advise]
[Sinovac Comments on SEC Findings Against Jiaqiang "Chiang" Li and 1Globe Capital SEC Order found Li and 1Globe Violated SEC Rules and Federal Securities Laws by Failing to Disclose Key Facts regarding their Holdings of Sinovac The SEC also found that the participants in the activist plan were advise]
[Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE --- Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques BEIJING, China, May 6, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a lea]
[Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE --- Inactivated vaccine for SARS-CoV-2 shows good safety and efficacy on Rhesus Macaques BEIJING, China, May 6, 2020 /Business Wire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a lea]
[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]
[Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F Fourth Quarter and Full Year 2019 Financial Summary Ÿ Sales for the fourth quarter of 2019 were $81.1 million, an increase of 52.4% from $53.2 million in the prior year period. Ÿ Sales in 2019 w]
[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]
[CONTENTS] [SPECIMEN * NOT VALID UNLESS COUNTERSIGNED BY TRANSFER AGENT * INCORPORATED UNDER THE LAWS OF THE GOVERNMENT OF ANTIGUA Number Sinovac Shares BIOTECH LTD. This Certifies that Is the Owner of Fully paid and non-assessable shares of Common Stock of Sinovac Biotech Ltd. transferable on the bo]
